Circulating Meteorin-like Levels in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis

Author(s): Qian Wu, Yi-Lin Dan, Yi-Sheng He, Kun Xiang, Yu-Qian Hu, Chan-Na Zhao, Xing Zhong, De-Guang Wang, Hai-Feng Pan*

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 44 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Meteorin-like (Metrnl) is a newly identified adipokine implicated in the pathogenesis of type 2 diabetes mellitus (T2DM), yet data on the circulating levels of Metrnl in patients with T2DM are controversial. To derive a more precise estimation on circulating Metrnl levels in T2DM patients, we conducted this meta-analysis.

Methods: The existing studies on the circulating levels of Metrnl in patients with T2DM published up to 16 January 2020 were comprehensively retrieved from PubMed, Web of Science, EMBASE, and The Cochrane library database. Pooled standard mean difference (SMD) with 95% confidence interval (CI) was calculated using random-effects model. Heterogeneity was assessed and quantified by Cochrane’s Q and I2 statistic. All statistical analyses were performed using Stata 12.0 software.

Results: Nine studies with 867 T2DM patients and 831 normal glucose tolerance (NGT) controls were included in the final analysis according to the inclusion criteria. No significant difference in circulating Metrnl levels was found between T2DM patients and NGT individuals (pooled SMD = -0.429, 95% CI = -1.077 to 0.219). Compared to controls, circulating Metrnl levels were significantly higher in the subgroups with BMI <25 kg/m2, using plasma sample and patient sample size ≥100, while circulating Metrnl levels were significantly lower in subgroups with age ≤50 years and homeostatic model assessment for insulin resistance (HOMA-IR) ≥4.

Conclusion: This meta-analysis indicates no significant change in circulating Metrnl levels in T2DM patients. However, this result may be influenced by age, BMI, sample type, HOMA-IR and patients sample size. Further longitudinal studies are warranted to offer more insights into the relationship between Metrnl and T2DM.

Keywords: Type 2 diabetes mellitus, Meteorin-like, interleukin-41, insulin resistance, meta-analysis, T2DM.

[1]
Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature 2001; 414(6865): 788-91.
[http://dx.doi.org/10.1038/414788a] [PMID: 11742410]
[2]
Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414(6865): 799-806.
[http://dx.doi.org/10.1038/414799a] [PMID: 11742412]
[3]
Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414(6865): 782-7.
[http://dx.doi.org/10.1038/414782a] [PMID: 11742409]
[4]
Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11(2): 85-97.
[http://dx.doi.org/10.1038/nri2921] [PMID: 21252989]
[5]
Zheng SL, Li ZY, Song J, Liu JM, Miao CY. Metrnl: A secreted protein with new emerging functions. Acta Pharmacol Sin 2016; 37(5): 571-9.
[http://dx.doi.org/10.1038/aps.2016.9] [PMID: 27063217]
[6]
Ost M, Coleman V, Kasch J, Klaus S. Regulation of myokine expression: Role of exercise and cellular stress. Free Radic Biol Med 2016; 98: 78-89.
[http://dx.doi.org/10.1016/j.freeradbiomed.2016.02.018] [PMID: 26898145]
[7]
Bridgewood C, Russell T, Weedon H, et al. The novel cytokine Metrnl/IL-41 is elevated in Psoriatic Arthritis synovium and inducible from both entheseal and synovial fibroblasts. Clin Immunol 2019; 208: 108253.
[http://dx.doi.org/10.1016/j.clim.2019.108253] [PMID: 31470086]
[8]
Jørgensen JR, Fransson A, Fjord-Larsen L, et al. Cometin is a novel neurotrophic factor that promotes neurite outgrowth and neuroblast migration in vitro and supports survival of spiral ganglion neurons in vivo. Exp Neurol 2012; 233(1): 172-81.
[PMID: 21985865]
[9]
Löffler D, Landgraf K, Rockstroh D, et al. METRNL decreases during adipogenesis and inhibits adipocyte differentiation leading to adipocyte hypertrophy in humans. Int J Obes 2017; 41(1): 112-9.
[PMID: 27748745]
[10]
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28(7): 412-9.
[PMID: 3899825]
[11]
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25(9): 603-5.
[http://dx.doi.org/10.1007/s10654-010-9491-z] [PMID: 20652370]
[12]
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014; 14: 135.
[http://dx.doi.org/10.1186/1471-2288-14-135] [PMID: 25524443]
[13]
Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res 2018; 27(6): 1785-805.
[http://dx.doi.org/10.1177/0962280216669183] [PMID: 27683581]
[14]
Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods 2010; 1(2): 97-111.
[http://dx.doi.org/10.1002/jrsm.12] [PMID: 26061376]
[15]
Lee YH, Song GG. Association between circulating leptin levels and systemic lupus erythematosus: An updated meta-analysis. Lupus 2018; 27(3): 428-35.
[http://dx.doi.org/10.1177/0961203317725587] [PMID: 28795654]
[16]
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629-34.
[http://dx.doi.org/10.1136/bmj.315.7109.629] [PMID: 9310563]
[17]
AlKhairi I, Cherian P, Abu-Farha M, et al. Increased Expression of meteorin-like hormone in type 2 diabetes and obesity and its association with Irisin. Cells 2019; 8(10): 8.
[http://dx.doi.org/10.3390/cells8101283] [PMID: 31635130]
[18]
Wang C, Pan Y, Song J, et al. Serum Metrnl level is correlated with insulin resistance, but not with β-cell function in type 2 diabetics. Med Sci Monit 2019; 25: 8968-74.
[http://dx.doi.org/10.12659/MSM.920222] [PMID: 31766048]
[19]
El-Ashmawy HM, Selim FO, Hosny TAM, Almassry HN. Association of low serum Meteorin like (Metrnl) concentrations with worsening of glucose tolerance, impaired endothelial function and atherosclerosis. Diabetes Res Clin Pract 2019; 150: 57-63.
[http://dx.doi.org/10.1016/j.diabres.2019.02.026] [PMID: 30825562]
[20]
Wang K, Li F, Wang C, et al. Serum levels of meteorin-like (metrnl) are increased in patients with newly diagnosed type 2 diabetes mellitus and are associated with insulin resistance. Med Sci Monit 2019; 25: 2337-43.
[http://dx.doi.org/10.12659/MSM.915331] [PMID: 30928991]
[21]
Chung HS, Hwang SY, Choi JH, et al. Implications of circulating Meteorin-like (Metrnl) level in human subjects with type 2 diabetes. Diabetes Res Clin Pract 2018; 136: 100-7.
[http://dx.doi.org/10.1016/j.diabres.2017.11.031] [PMID: 29199003]
[22]
Dadmanesh M, Aghajani H, Fadaei R, Ghorban K. Lower serum levels of Meteorin-like/Subfatin in patients with coronary artery disease and type 2 diabetes mellitus are negatively associated with insulin resistance and inflammatory cytokines. PLoS One 2018; 13(9): e0204180.
[http://dx.doi.org/10.1371/journal.pone.0204180] [PMID: 30212581]
[23]
Fadaei R, Dadmanesh M, Moradi N, et al. Serum levels of subfatin in patients with type 2 diabetes mellitus and its association with vascular adhesion molecules. Arch Physiol Biochem 2018; 1-6.
[http://dx.doi.org/10.1080/13813455.2018.1538248] [PMID: 30463448]
[24]
Zheng SL, Li ZY, Zhang Z, Wang DS, Xu J, Miao CY. Evaluation of two commercial enzyme-linked immunosorbent assay kits for the detection of human circulating Metrnl. Chem Pharm Bull (Tokyo) 2018; 66: 391-8.
[25]
Lee JH, Kang YE, Kim JM, et al. Serum Meteorin-like protein levels decreased in patients newly diagnosed with type 2 diabetes. Diabetes Res Clin Pract 2018; 135: 7-10.
[http://dx.doi.org/10.1016/j.diabres.2017.10.005] [PMID: 29097285]
[26]
Akash MS, Rehman K, Chen S. Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J Cell Biochem 2013; 114(3): 525-31.
[http://dx.doi.org/10.1002/jcb.24402] [PMID: 22991242]
[27]
Jaganathan R, Ravindran R, Dhanasekaran S. Emerging role of adipocytokines in type 2 diabetes as mediators of insulin resistance and cardiovascular disease. Can J Diabetes 2018; 42(4): 446-456.e1.
[http://dx.doi.org/10.1016/j.jcjd.2017.10.040] [PMID: 29229313]
[28]
Li ZY, Zheng SL, Wang P, et al. Subfatin is a novel adipokine and unlike Meteorin in adipose and brain expression. CNS Neurosci Ther 2014; 20(4): 344-54.
[http://dx.doi.org/10.1111/cns.12219] [PMID: 24393292]
[29]
Ushach I, Burkhardt AM, Martinez C, et al. meteorin-like is a cytokine associated with barrier tissues and alternatively activated macrophages. Clin Immunol 2015; 156(2): 119-27.
[http://dx.doi.org/10.1016/j.clim.2014.11.006] [PMID: 25486603]
[30]
Boström P, Wu J, Jedrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481(7382): 463-8.
[http://dx.doi.org/10.1038/nature10777] [PMID: 22237023]
[31]
Rao RR, Long JZ, White JP, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell 2014; 157(6): 1279-91.
[http://dx.doi.org/10.1016/j.cell.2014.03.065] [PMID: 24906147]
[32]
Jung TW, Lee SH, Kim HC, et al. METRNL attenuates lipid-induced inflammation and insulin resistance via AMPK or PPARδ-dependent pathways in skeletal muscle of mice. Exp Mol Med 2018; 50(9): 122.
[http://dx.doi.org/10.1038/s12276-018-0147-5] [PMID: 30213948]
[33]
López-Suárez A. Burden of cancer attributable to obesity, type 2 diabetes and associated risk factors. Metabolism 2019; 92: 136-46.
[http://dx.doi.org/10.1016/j.metabol.2018.10.013] [PMID: 30412695]
[34]
Dekkers OM. Meta-analysis: Key features, potentials and misunderstandings. Research and practice in thrombosis and haemostasis 2018; 2: 658-3.
[http://dx.doi.org/10.1002/rth2.12153]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 44
Year: 2020
Published on: 07 October, 2020
Page: [5732 - 5738]
Pages: 7
DOI: 10.2174/1381612826666201007163930
Price: $65

Article Metrics

PDF: 32
HTML: 1